美国 · SEC FORM 4
LEXICON PHARMACEUTICALS, INC.
LXRX · Nasdaq · CIK 0001062822 · Healthcare · Biotechnology
内部人信号
当前没有活跃买入信号
0 qualifying P purchase groups
当前 180 天评分窗口
8 同一窗口内观察到的 Form 4 交易行
0 sales · 8 期权、代扣税、授予、赠与或其他交易行
最近一次合资格买入2026-02-25 · DEBBANE RAYMOND · $3.0K
为什么没有活跃信号？
买入活动无
近期买入无
近期卖出无
买入信号状态未激活
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
Cluster未计算
买入规模未计算
角色未计算
近期性未计算
确信度未计算
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
AprMayJunJulAugSepOct
Swain Judith LDirector
○
Sullivan Diane E.Director
○
SOBECKI CHRISTOPHER JDirector
○
Cheung IvanDirector
○
BARKER SAM LDirector
○
Amouyal PhilippeDirector
○
● 买入▼ 卖出○ 其他
Showing the six most active owners; 2 additional owner(s) remain in Form 4 申报证据.
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
暂无已记录的活跃信号快照
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2026-02-25 · DEBBANE RAYMOND.
近期 Form 4 活动
8买入
0卖出
37其他 Form 4 交易行
22SEC 申报 · 365天
买入0 qualifying P line(s) · 180 days
卖出0 sale line(s) · 仅供背景
其他8 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not assessed
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 25,828,112
- 上期报告
- 28,793,507
- 日均成交量
- 4,190,453
- 回补天数
- 6.2
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-02-25 | DEBBANE RAYMOND | 买入 (P) | Common Stock | 2,000 | USD 1.49 | USD 2,980 | SEC 申报 ↗ |
| 2026-02-23 | DEBBANE RAYMOND | 买入 (P) | Common Stock | 100,000 | USD 1.47 | USD 147,000 | SEC 申报 ↗ |
| 2026-02-20 | DEBBANE RAYMOND | 买入 (P) | Common Stock | 100,000 | USD 1.48 | USD 148,000 | SEC 申报 ↗ |
| 2026-02-19 | DEBBANE RAYMOND | 买入 (P) | Common Stock | 50,000 | USD 1.44 | USD 72,000 | SEC 申报 ↗ |
| 2026-02-18 | DEBBANE RAYMOND | 买入 (P) | Common Stock | 133,688 | USD 1.32 | USD 176,468 | SEC 申报 ↗ |
| 2026-02-17 | DEBBANE RAYMOND | 买入 (P) | Common Stock | 76,857 | USD 1.31 | USD 100,683 | SEC 申报 ↗ |
| 2026-02-13 | DEBBANE RAYMOND | 买入 (P) | Common Stock | 57,952 | USD 1.31 | USD 75,917 | SEC 申报 ↗ |
| 2026-02-02 | Artal Group S.A.; Artal International Management S.A.; Artal International S.C.A.; Artal Participations S.a r.l.; DEBBANE RAYMOND; Invus Global Management, LLC; Siren, L.L.C.; Stichting Administratiekantoor Westend; Westend S.A. | 买入 (P) | Common Stock | 1,538,462 | USD 1.30 | USD 2,000,001 | SEC 申报 ↗ |
| 2023-11-16 | COATS LONNEL | 买入 (P) | Common Stock | 90,000 | USD 1.05 | USD 94,500 | SEC 申报 ↗ |
| 2023-11-13 | Amouyal Philippe | 买入 (P) | Common Stock | 200,000 | USD 1.01 | USD 202,000 | SEC 申报 ↗ |
| 2023-11-10 | COATS LONNEL | 买入 (P) | Common Stock | 10,000 | USD 1.01 | USD 10,100 | SEC 申报 ↗ |
| 2023-10-12 | DEBBANE RAYMOND | 买入 (P) | Common Stock | 148,820 | USD 1.03 | USD 153,285 | SEC 申报 ↗ |
| 2023-10-11 | DEBBANE RAYMOND | 买入 (P) | Common Stock | 342,874 | USD 1.08 | USD 370,304 | SEC 申报 ↗ |
| 2023-10-10 | DEBBANE RAYMOND | 买入 (P) | Common Stock | 508,306 | USD 1.14 | USD 579,469 | SEC 申报 ↗ |
| 2023-09-14 | WADE JEFFREY L | 买入 (P) | Common Stock | 10,000 | USD 1.38 | USD 13,800 | SEC 申报 ↗ |
Form 4 申报证据
45 transaction lines in the latest 365-day window; 314 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-03 | Swain Judith L | 期权行权／转换 (M) | Common Stock | 89,312 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-03 | Sullivan Diane E. | 期权行权／转换 (M) | Common Stock | 89,312 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-03 | SOBECKI CHRISTOPHER J | 期权行权／转换 (M) | Common Stock | 89,312 | USD 0.00 | USD 0 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-03 | Swain Judith L | 期权行权／转换 (M) | Common Stock | 89,312 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-03 | Sullivan Diane E. | 期权行权／转换 (M) | Common Stock | 89,312 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-03 | SOBECKI CHRISTOPHER J | 期权行权／转换 (M) | Common Stock | 89,312 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-03 | DEBBANE RAYMOND | 期权行权／转换 (M) | Common Stock | 89,312 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-03 | Cheung Ivan | 期权行权／转换 (M) | Common Stock | 89,312 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-03 | BARKER SAM L | 期权行权／转换 (M) | Common Stock | 89,312 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-03 | Amouyal Philippe | 期权行权／转换 (M) | Common Stock | 89,312 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-04-30 | Artal Group S.A.; Artal International Management S.A.; Artal International S.C.A.; Artal Participations S.a r.l.; Stichting Administratiekantoor Westend; Westend S.A.; Wittouck Amaury | 期权行权／转换 (M) | Common Stock | 20,421,735 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-28 | McDermott Wendy | 期权行权／转换 (M) | Common Stock | 224,406 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-28 | McDermott Wendy | 代扣税 (F) | Common Stock | 68,107 | USD 1.47 | USD 100,117 | SEC 申报 ↗ |
| 2026-02-28 | Martens Rachel Yap | 期权行权／转换 (M) | Common Stock | 67,090 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-28 | Martens Rachel Yap | 代扣税 (F) | Common Stock | 35,826 | USD 1.47 | USD 52,664 | SEC 申报 ↗ |
| 2026-02-28 | Granowitz Craig B | 期权行权／转换 (M) | Common Stock | 312,276 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-28 | Granowitz Craig B | 代扣税 (F) | Common Stock | 109,098 | USD 1.47 | USD 160,374 | SEC 申报 ↗ |
| 2026-02-28 | Gopinathan Suma | 期权行权／转换 (M) | Common Stock | 99,950 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-28 | Gopinathan Suma | 代扣税 (F) | Common Stock | 24,338 | USD 1.47 | USD 35,777 | SEC 申报 ↗ |
| 2026-02-28 | Exton Michael | 期权行权／转换 (M) | Common Stock | 503,263 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-28 | Exton Michael | 代扣税 (F) | Common Stock | 204,831 | USD 1.47 | USD 301,102 | SEC 申报 ↗ |
| 2026-02-28 | DeFrancesco Lisa | 期权行权／转换 (M) | Common Stock | 152,864 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-28 | DeFrancesco Lisa | 代扣税 (F) | Common Stock | 74,572 | USD 1.47 | USD 109,621 | SEC 申报 ↗ |
| 2026-02-28 | Crum Brian T | 期权行权／转换 (M) | Common Stock | 273,006 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-28 | Crum Brian T | 代扣税 (F) | Common Stock | 105,019 | USD 1.47 | USD 154,378 | SEC 申报 ↗ |
| 2026-02-28 | Coiante Scott M | 期权行权／转换 (M) | Common Stock | 160,237 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-28 | Coiante Scott M | 代扣税 (F) | Common Stock | 54,881 | USD 1.47 | USD 80,675 | SEC 申报 ↗ |
| 2026-02-25 | DEBBANE RAYMOND | 买入 (P) | Common Stock | 2,000 | USD 1.49 | USD 2,980 | SEC 申报 ↗ |
| 2026-02-23 | DEBBANE RAYMOND | 买入 (P) | Common Stock | 100,000 | USD 1.47 | USD 147,000 | SEC 申报 ↗ |
| 2026-02-20 | DEBBANE RAYMOND | 买入 (P) | Common Stock | 100,000 | USD 1.48 | USD 148,000 | SEC 申报 ↗ |
| 2026-02-19 | DEBBANE RAYMOND | 买入 (P) | Common Stock | 50,000 | USD 1.44 | USD 72,000 | SEC 申报 ↗ |
| 2026-02-18 | DEBBANE RAYMOND | 买入 (P) | Common Stock | 133,688 | USD 1.32 | USD 176,468 | SEC 申报 ↗ |
| 2026-02-17 | Artal Group S.A.; Artal International Management S.A.; Artal International S.C.A.; Artal Participations S.a r.l.; Stichting Administratiekantoor Westend; Westend S.A.; Wittouck Amaury | 奖励／授予 (A) | Series B Convertible Preferred Stock | 41,290 | USD 65.00 | USD 2,683,823 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | LXRX |
| CIK | 0001062822 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 314 transaction lines from 2020-02-28 to 2026-06-03 31 P purchase lines · 2 S sale lines · 281 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.